Summary
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609
alone to participants with select advanced solid tumors and then in combination with
fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose
expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609
in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal
adenocarcinoma (PDAC) .